Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 401, Issue 1, 2010, Pages 13-19

  Kalle, Arunasree M ^a   Mallika, A ^a   Badiger, Jayasree ^b   Alinakhi, ^a   Talukdar, Pinaki ^c   Sachchidanand, ^d  

^a INSTITUTE OF LIFE SCIENCES   (India)

^b VG College for Women   (India)

^c INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

^d LUPIN LIMITED   (India)

Author keywords

P53 mediated apoptosis; SIRT1; Sirtinol; Suramin

Indexed keywords

CASPASE; JGB 1741; PROTEIN BAX; PROTEIN BCL 2; PROTEIN INHIBITOR; SIRTINOL; SIRTUIN 1; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRAIN K 562; CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; MEDICINAL CHEMISTRY; METASTASIS; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE;

APOPTOSIS; BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; NAPHTHOLS; SIRTUIN 1; THIOPHENES;

EID: 77957684701     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.118     Document Type: Article

References (41)

1. Tissenbaum H.A., Guarente L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 2001, 410:227-230.
2. Frye R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun. 2000, 273:793-798.
3. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
4. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. HSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
5. Yeung F., Hoberg J.E., Ramsey C.S., Keller M.D., Jones D.R., Frye R.A., Mayo M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004, 23:2369-2380.
6. Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W., Bultsma Y., McBurney M., Guarente L. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004, 116:551-563.
7. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
8. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., Tran H., Ross S.E., Mostoslavsky R., Cohen H.Y., Hu L.S., Cheng H.L., Jedrychowski M.P., Gygi S.P., Sinclair D.A., Alt F.W., Greenberg M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
9. Picard F., Kurtev M., Chung N., Topark-Ngarm A., Senawong T., Machado De Oliveira R., Leid M., McBurney M.W., Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004, 429:771-776.
10. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
11. Nisoli E., Tonello C., Cardile A., Cozzi V., Bracale R., Tedesco L., Falcone S., Valerio A., Cantoni O., Clementi E., Moncada S., Carruba M.O. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 2005, 310:314-317.
12. Greer E.L., Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005, 24:7410-7425.
13. Ford J., Jiang M., Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005, 65:10457-10463.
14. Bedalov A., Gatbonton T., Irvine W.P., Gottschling D.E., Simon J.A. Identification of a small molecule inhibitor of Sir2p. Proc. Natl. Acad. Sci. USA 2001, 98:15113-15118.
15. Grozinger C.M., Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem. Biol. 2002, 9:3-16.
16. Smith B.C., Denu J.M. Mechanism-based inhibition of Sir2 deacetylases by thioacetyl-lysine peptide. Biochemistry 2007, 46:14478-14486.
17. Smith K.T., Workman J.L. Histone deacetylase inhibitors: anticancer compounds. Int. J. Biochem. Cell Biol. 2009, 41:21-25.
18. Autiero I., Costantini S., Colonna G. Human sirt-1: molecular modeling and structure-function relationships of an unordered protein. PLoS One 2009, 4:e7350.
19. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
20. Huey R., Morris G.M., Olson A.J., Goodsell D.S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 2007, 28:1145-1152.
21. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., Jin L., Boss O., Perni R.B., Vu C.B., Bemis J.E., Xie R., Disch J.S., Ng P.Y., Nunes J.J., Lynch A.V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D.A., Olefsky J.M., Jirousek M.R., Elliott P.J., Westphal C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.
22. Plumb J.A. Cell sensitivity assays: the MTT assay. Methods Mol. Med. 2004, 88:165-169.
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
24. Chandra J., Niemer I., Gilbreath J., Kliche K.O., Andreeff M., Freireich E.J., Keating M., McConkey D.J. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998, 92:4220-4229.
25. Shechter D., Dormann H.L., Allis C.D., Hake S.B. Extraction, purification and analysis of histones. Nat. Protoc. 2007, 2:1445-1457.
26. Sperry J.B., Wright D.L. Furans, thiophenes and related heterocycles in drug discovery. Curr. Opin. Drug Discov. Devel. 2005, 8:723-740.
27. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
28. Gewald K., Schinke E., Böttcher H. Heterocyclen aus CH-aciden Nitrilen, VIII. 2-Amino-thiophene aus methylenaktiven Nitrilen, Carbonylverbindungen und Schwefel. Chemische Berichte 1966, 99:94-100.
29. Aurelio L., Valant C., Figler H., Flynn B.L., Linden J., Sexton P.M., Christopoulos A., Scammells P.J. 3- and 6-Substituted 2-amino-4,5,6,7-tetrahydrothieno[2,3-c]pyridines as A1 adenosine receptor allosteric modulators and antagonists. Bioorg. Med. Chem. 2009, 17:7353-7361.
30. Canpolat E., Kaya M. Studies on mononuclear chelates derived from substituted Schiff-base ligands (part 7): synthesis and characterization of a new naphthyliden-p-aminoacetophenoneoxime and its complexes with Co(II), Ni(II), Cu(II) and Zn(II). J. Coord. Chem. 2005, 58:1063-1069.
31. Trapp J., Meier R., Hongwiset D., Kassack M.U., Sippl W., Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem 2007, 2:1419-1431.
32. Larsen A.K. Suramin: an anticancer drug with unique biological effects. Cancer Chemother. Pharmacol. 1993, 32:96-98.
33. Lara E., Mai A., Calvanese V., Altucci L., Lopez-Nieva P., Martinez-Chantar M.L., Varela-Rey M., Rotili D., Nebbioso A., Ropero S., Montoya G., Oyarzabal J., Velasco S., Serrano M., Witt M., Villar-Garea A., Inhof A., Mato J.M., Esteller M., Fraga M.F. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2008, 28:781-791.
34. Heltweg B., Gatbonton T., Schuler A.D., Posakony J., Li H., Goehle S., Kollipara R., Depinho R.A., Gu Y., Simon J.A., Bedalov A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006, 66:4368-4377.
35. Ota H., Tokunaga E., Chang K., Hikasa M., Iijima K., Eto M., Kozaki K., Akishita M., Ouchi Y., Kaneki M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006, 25:176-185.
36. Stein C.A. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res. 1993, 53:2239-2248.
37. Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P., Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 2004, 16:93-105.
38. Lara E., Mai A., Calvanese V., Altucci L., Lopez-Nieva P., Martinez-Chantar M.L., Varela-Rey M., Rotili D., Nebbioso A., Ropero S., Montoya G., Oyarzabal J., Velasco S., Serrano M., Witt M., Villar-Garea A., Imhof A., Mato J.M., Esteller M., Fraga M.F. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009, 28:781-791.
39. Jolma I.W., Ni X.Y., Rensing L., Ruoff P. Harmonic oscillations in homeostatic controllers: dynamics of the p53 regulatory system. Biophys. J. 2010, 98:743-752.
40. Chipuk J.E., Green D.R. Cytoplasmic p53: bax and forward. Cell Cycle 2004, 3:429-431.
41. Green D.R., Chipuk J.E. Apoptosis: stabbed in the BAX. Nature 2008, 455:1047-1049.